According to the ETF Finder at ETF Channel, SRPT makes up 2.59% of the SPDR S&P Biotech ETF (XBI) which is lower by about 0.7% on the day Friday.
In afternoon trading Friday, SRPT was down about 0.2% on the day.
On Monday, PTC said the U.S. Food and Drug Administration denied an appeal of the Translarna refuse-to-file letter issued last February.
Are the Baker Brothers selling Seattle Genetics? Biomarin CEO throws shade on Sarepta. TG Therapeutics management adds to its credibility problem.